Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalAddictionDigital HealthTrial Update

Study on KIOS App for Opioid Use Disorder Effectiveness and Implementation

The KIOS app is being evaluated for its real-world effectiveness in aiding recovery from opioid addiction.

Published: August 6, 2026
Updated: August 6, 2026
Author: Humanexa Intelligence
Therapeutic area: Addiction / Digital Health
Company: digital health therapeutics
Asset: Study
Trial SummaryCLN

Phase III

Addiction / Digital Health

Status

Active

Sponsor

digital health therapeutics

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Why it matters

The evaluation of the KIOS app for opioid use disorder is significant as it may validate the role of digital health solutions in addiction treatment. Positive outcomes could shift investment strategies and competitive dynamics within the digital therapeutics sector.

Recommended action

Humanexa recommends Monitor.

Analysis

Monitor results from the study regarding user feedback and effectiveness metrics.

Related companies & assets

Companies

  • digital health therapeutics →

Assets

  • Study →

Sources & Humanexa intelligence

Source links

  • Study on KIOS App for Opioid Use Disorder Effectiveness and Implementation ↗

Related Humanexa pages

  • Study on KIOS App for Opioid Use Disorder Effectiveness and Implementation →

Related signals

Trial SummaryCLN

Phase III

Infectious Disease / Vaccines

Status

Active

Signal Score

8.4

Clinicalhigh signal

H5N6 Vaccine Shows Strong Immunogenicity in H5N1-Primed Adults

The MF59-adjuvanted H5N6 vaccine elicited strong cross-reactive immunity in H5N1-primed adults, with robust antibody responses persisting for at least 6 years.

August 7, 2026Read signal →
Trial SummaryCLN

Phase III

Infectious Disease / HIV

Status

Active

Signal Score

8.4

Clinicalhigh signal

STREAMS Study to Enhance Mental Health and HIV Care in Adolescents in Uganda

The STREAMS study aims to evaluate a combination intervention for mental health and adherence to HIV care among adolescents in Uganda.

August 6, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

  1. Home
  2. /Clinical
  3. /Study on KIOS App for Opioid Use Disorder Effectiveness and Implementation